|
|
| (6 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Abciximab#Contraindications]] |
| {{Abciximab}}
| |
| {{CMG}}; {{AE}} {{SS}}, {{PB}}
| |
| | |
| ==Contraindications==
| |
| | |
| Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:
| |
| | |
| * Active internal bleeding
| |
| * Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.
| |
| * History of [[CVA|cerebrovascular accident (CVA)]] within two years, or [[CVA]] with a significant residual neurological deficit
| |
| * Bleeding diathesis
| |
| * Administration of oral [[anticoagulant]]s within seven days unless [[prothrombin time]] is <1.2 times control
| |
| * [[Thrombocytopenia]] (<100 000 cells/m L)
| |
| * Recent (within six weeks) major surgery or [[trauma]]
| |
| * Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]]
| |
| * Severe uncontrolled [[hypertension]]
| |
| * Presumed or documented history of [[vasculitis]]
| |
| * Use of intravenous [[dextran]] before PCI, or intent to use it during an intervention
| |
| * Abciximab is also contraindicated in patients with known [[hypersensitivity]] to any component of this product or to murine proteins.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3#nlm34067-9 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |